These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 34145928

  • 1. Activated microglia do not increase 18 kDa translocator protein (TSPO) expression in the multiple sclerosis brain.
    Nutma E, Gebro E, Marzin MC, van der Valk P, Matthews PM, Owen DR, Amor S.
    Glia; 2021 Oct; 69(10):2447-2458. PubMed ID: 34145928
    [Abstract] [Full Text] [Related]

  • 2. A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis.
    Nutma E, Stephenson JA, Gorter RP, de Bruin J, Boucherie DM, Donat CK, Breur M, van der Valk P, Matthews PM, Owen DR, Amor S.
    Brain; 2019 Nov 01; 142(11):3440-3455. PubMed ID: 31578541
    [Abstract] [Full Text] [Related]

  • 3. Pro-inflammatory activation of primary microglia and macrophages increases 18 kDa translocator protein expression in rodents but not humans.
    Owen DR, Narayan N, Wells L, Healy L, Smyth E, Rabiner EA, Galloway D, Williams JB, Lehr J, Mandhair H, Peferoen LA, Taylor PC, Amor S, Antel JP, Matthews PM, Moore CS.
    J Cereb Blood Flow Metab; 2017 Aug 01; 37(8):2679-2690. PubMed ID: 28530125
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain.
    Cosenza-Nashat M, Zhao ML, Suh HS, Morgan J, Natividad R, Morgello S, Lee SC.
    Neuropathol Appl Neurobiol; 2009 Jun 01; 35(3):306-28. PubMed ID: 19077109
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of the Effect of Fingolimod Treatment on Microglial Activation Using Serial PET Imaging in Multiple Sclerosis.
    Sucksdorff M, Rissanen E, Tuisku J, Nuutinen S, Paavilainen T, Rokka J, Rinne J, Airas L.
    J Nucl Med; 2017 Oct 01; 58(10):1646-1651. PubMed ID: 28336784
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Characterization of cortico-meningeal translocator protein expression in multiple sclerosis.
    Herranz E, Treaba CA, Barletta VT, Mehndiratta A, Ouellette R, Sloane JA, Ionete C, Babu S, Mastantuono M, Magon S, Loggia ML, Makary MM, Hooker JM, Catana C, Kinkel RP, Nicholas R, Klawiter EC, Magliozzi R, Mainero C.
    Brain; 2024 Jul 05; 147(7):2566-2578. PubMed ID: 38289855
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Brain TSPO-PET predicts later disease progression independent of relapses in multiple sclerosis.
    Sucksdorff M, Matilainen M, Tuisku J, Polvinen E, Vuorimaa A, Rokka J, Nylund M, Rissanen E, Airas L.
    Brain; 2020 Dec 05; 143(11):3318-3330. PubMed ID: 33006604
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Association of serum neurofilament light with microglial activation in multiple sclerosis.
    Saraste M, Matilainen M, Vuorimaa A, Laaksonen S, Sucksdorff M, Leppert D, Kuhle J, Airas L.
    J Neurol Neurosurg Psychiatry; 2023 Sep 05; 94(9):698-706. PubMed ID: 37130728
    [Abstract] [Full Text] [Related]

  • 15. Longitudinal stability of progression-related microglial activity during teriflunomide treatment in patients with multiple sclerosis.
    Lehto J, Nylund M, Matilainen M, Sucksdorff M, Vuorimaa A, Rajander J, Wahlroos S, Hariri P, Airas L.
    Eur J Neurol; 2023 Aug 05; 30(8):2365-2375. PubMed ID: 37154404
    [Abstract] [Full Text] [Related]

  • 16. Insights into disseminated MS brain pathology with multimodal diffusion tensor and PET imaging.
    Bezukladova S, Tuisku J, Matilainen M, Vuorimaa A, Nylund M, Smith S, Sucksdorff M, Mohammadian M, Saunavaara V, Laaksonen S, Rokka J, Rinne JO, Rissanen E, Airas L.
    Neurol Neuroimmunol Neuroinflamm; 2020 May 05; 7(3):. PubMed ID: 32123046
    [Abstract] [Full Text] [Related]

  • 17. Regulation of microglial TMEM119 and P2RY12 immunoreactivity in multiple sclerosis white and grey matter lesions is dependent on their inflammatory environment.
    van Wageningen TA, Vlaar E, Kooij G, Jongenelen CAM, Geurts JJG, van Dam AM.
    Acta Neuropathol Commun; 2019 Dec 11; 7(1):206. PubMed ID: 31829283
    [Abstract] [Full Text] [Related]

  • 18. Individual Mapping of Innate Immune Cell Activation Is a Candidate Marker of Patient-Specific Trajectories of Worsening Disability in Multiple Sclerosis.
    Bodini B, Poirion E, Tonietto M, Benoit C, Palladino R, Maillart E, Portera E, Battaglini M, Bera G, Kuhnast B, Louapre C, Bottlaender M, Stankoff B.
    J Nucl Med; 2020 Jul 11; 61(7):1043-1049. PubMed ID: 32005777
    [Abstract] [Full Text] [Related]

  • 19. Loss of 'homeostatic' microglia and patterns of their activation in active multiple sclerosis.
    Zrzavy T, Hametner S, Wimmer I, Butovsky O, Weiner HL, Lassmann H.
    Brain; 2017 Jul 01; 140(7):1900-1913. PubMed ID: 28541408
    [Abstract] [Full Text] [Related]

  • 20. Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis.
    Datta G, Colasanti A, Rabiner EA, Gunn RN, Malik O, Ciccarelli O, Nicholas R, Van Vlierberghe E, Van Hecke W, Searle G, Santos-Ribeiro A, Matthews PM.
    Brain; 2017 Nov 01; 140(11):2927-2938. PubMed ID: 29053775
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.